Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study
- 3 July 1999
- Vol. 319 (7201), 23-24
- https://doi.org/10.1136/bmj.319.7201.23
Abstract
The rate of progression to new AIDS defining events has been reduced considerably since the introduction of potent antiretroviral combination therapy.1 2 It is unclear, however, whether the reduction has been the same for all opportunistic infections and malignancies, or whether the effect has been greater for some conditions than for others. We examined this question in the Swiss HIV Cohort Study, a large community cohort of adults with HIV infection. The study methods are described in detail elsewhere.1 3 The cohort includes the majority of people with advanced HIV infection in Switzerland. Potent antiretroviral combination therapy (triple combinations including at least one protease inhibitor) was gradually introduced from 1995 onwards. By mid-1997, 70% of patients with a history of CD4 cell counts below 200 × 106/l were receiving this treatment. The incidence of all new AIDS …Keywords
This publication has 5 references indexed in Scilit:
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Spectrum of AIDS-associated malignant disordersThe Lancet, 1998
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre studyBMJ, 1997
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994
- The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristicsInternational Journal of Public Health, 1994